Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bisoprolol fumarate -

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bisoprolol fumarate, quantity: 3.75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; calcium hydrogen phosphate; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - bisoprolol fumarate, quantity: 7.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; calcium hydrogen phosphate; crospovidone; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

unit dose services - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 25 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1000 mg - granules, modified release - excipient ingredients: simethicone; aspartame; microcrystalline cellulose; triethyl citrate; colloidal anhydrous silica; citric acid; carmellose sodium; magnesium stearate; purified talc; titanium dioxide; povidone; methacrylic acid copolymer; hypromellose; flavour - salofalk granules are indicated for the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 500 mg - granules, modified release - excipient ingredients: colloidal anhydrous silica; purified talc; povidone; aspartame; titanium dioxide; methacrylic acid copolymer; magnesium stearate; triethyl citrate; microcrystalline cellulose; carmellose sodium; simethicone; citric acid; hypromellose; flavour - salofalk granules are indicated for the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - indometacin, quantity: 25 mg - capsule, hard - excipient ingredients: iron oxide yellow; magnesium stearate; lecithin; lactose monohydrate; gelatin; titanium dioxide; colloidal anhydrous silica; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - indocid is indicated in active stage of: rheumatoid arthritis, osteoarthritis, degenerative joint disease of the hip, ankylosing spondylitis, gout. it is also indicated for: acute musculoskeletal disorders, such as bursitis, tendonitis, synovitis, tenosynovitis, tenosynovitis, capsulitis of the shoulder, sprains and strains; low back pain (commonly referred to as lumbago); inflammation, pain and oedema following orthopaedic surgical procedures and nonsurgical procedures associated with reduction and immobilisation of fractures or dislocations; pain and associated symptoms of primary dysmenorrhoea.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lithium carbonate, quantity: 250 mg - tablet, film coated - excipient ingredients: dextrin; lactose monohydrate; macrogol 6000; sodium starch glycollate type a; purified talc; sodium lauryl sulfate; magnesium stearate; hypromellose; maize starch - mania, both as treatment and prophylaxis; manic depressive (bipolar) illness, both as treatment and as prophylaxis; it is less effective in depressive swings. in recurrent endogenous (unipolar) depressive illness, it is highly effective as prophylaxis in a number of cases, and is probably useful as treatment, especially if there is a family history of manic depressive illness and response to lithium. in some cases of schizoaffective illness and so called chronic schizophrenia it is dramatically effective. those in the latter category who do respond have frequently had affective symptoms at some time. it is used in character or personality disorders in young people with clear evidence of cyclothymia. lithium should not be prescribed until it is certain that the manic depressive swings are established and the course of the disease certain. if the patient has two affective swings in one year, perhaps in opposite directions, and associated with a positive family history, it should certainly be seriously considered. with three episodes in two years, there is no doubt it should be given. as a general rule, it should be prescribed, and therapeutic response assessed, satisfactory maintenance dosage determined, side and toxic effects and associated precautions discussed with the patient and relatives, and blood levels monitored, only under specialist supervision except perhaps in isolated areas. a major management problem also is that there are relatively narrow distances between the therapeutic and toxic dosages and blood levels. for these reasons treatment is preferably commenced on an inpatient basis, so that the patient is under appropriate observation.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ephedrine sulfate, quantity: 30 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - ephedrine is indicated in the treatment of shock unresponsive to fluid replacement. it is also indicated in the treatment of hypotension secondary to spinal anaesthesia. ephedrine sulfate injection has also been used in the treatment of bronchial asthma and reversible bronchospasm although more selective agents (beta adrenergic agonists) are now available.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - terbinafine hydrochloride, quantity: 281.25 mg (equivalent: terbinafine, qty 250 mg) - tablet - excipient ingredients: hypromellose; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate - treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infection caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.